Immunotherapy in Melanoma | Specialty

The OncLive Immunotherapy in Melanoma condition center page is a comprehensive resource for clinical news and expert insights on available and investigational immunotherapies in melanoma and other skin cancers. This page features news articles, interviews in written and video format, and podcasts that focus on updates with checkpoint inhibitors and the ongoing research with this type of treatment.

Dr. Ribas on Combining Vemurafenib and Ipilimumab

October 9th 2012

Antoni Ribas, MD, from the UCLA Jonsson Comprehensive Cancer Center, discusses a phase I/II trial combining vemurafenib and ipilimumab for metastatic melanoma.

New Metastatic Melanoma Therapies Create Hope for Patients, Key Role for Oncology Nurses

October 8th 2012

The incidence of melanoma, the deadliest of all skin cancers, is quickly rising, and the disease is responsible for more than 8000 deaths each year.

Long-Term Data Show Significant Improvement in Survival With Ipilimumab in Melanoma

October 3rd 2012

Nearly twice as many patients with metastatic melanoma who received a combination of ipilimumab and dacarbazine were alive after four years, suggesting that ipilimumab has long-term survival benefits.

BRAF Inhibitor Plus MEK Inhibitor Encouraging in Metastatic Melanoma

September 29th 2012

Combining the new drugs dabrafenib and trametinib provided a clinically meaningful improvement in patients with melanoma that had BRAF V600 mutations.

Dual Mutations No Obstacle to Targeted Melanoma Therapy

September 28th 2012

Concurrent mutations in MEK1 and BRAF genes do not confer resistance to BRAF inhibitors in advanced melanoma, contrary to what investigators had expected.

Vismodegib Effective Against Skin Cancer in Patients With Basal-Cell Nevus Syndrome

August 31st 2012

The oral hedgehog pathway inhibitor vismodegib is effective for both the prevention and treatment of basal-cell carcinoma in patients with the rare disorder known as basal-cell nevus syndrome.

Dr. Sekulic on the Hedgehog Pathway Inhibitor Vismodegib

August 30th 2012

Dr. Aleksandar Sekulic, from the Mayo Clinic in Arizona, on the Hedgehog Pathway Inhibitor Vismodegib for Basal Cell Carcinoma.

Targeted PD-1 Therapy Offers Opportunity to Sequence Agents

August 30th 2012

Drugs that target the programmed death-1 pathway hold considerable promise for the treatment of patients with melanoma, particularly in integrating the agents into the sequence of therapy.

Dr. Ribas on MAPK Inhibition With Dabrafenib and Trametinib

August 23rd 2012

Dr. Antoni Ribas, from UCLA Jonsson Comprehensive Cancer Center, on the Benefits of MAPK Inhibition With Dabrafenib and Trametinib

NDAs Filed for Two Melanoma Drugs

August 7th 2012

GlaxoSmithKline is seeking the FDA's approval for single-agent use of dabrafenib and trametinib, two targeted therapies for the treatment of patients with metastatic melanoma who harbor BRAF V600 gene mutations.

ï»¿Combining Novel Therapeutics: Strategies Emerge for Employing Both New Options in Melanoma

July 26th 2012

It is difficult to overstate the excitement surrounding the development of two new effective therapeutic strategies in the management of metastatic melanoma.

Ingenol Mebutate Gel Is Effective and Safe for Actinic Keratosis

July 12th 2012

Field-directed treatment with the investigational topical agent ingenol mebutate has been shown to be effective for actinic keratoses on the head and body.

Dr. Kris on the Combination of Targeted Therapies

July 6th 2012

Dr. Mark Kris, from Memorial Sloan-Kettering Cancer Center, on the Combination of Molecularly Targeted Therapies.

Dr. Grunberg Describes the MASCC International Symposium

June 29th 2012

Dr. Steven Grunberg, from the Vermont Cancer Center, Describes the 2012 Multinational Association of Supportive Care in Cancer Symposium.

High Points and Hurdles: Immunotherapy Moves Forward

June 27th 2012

Immunotherapy is maintaining its momentum in clinical development programs, with explorations under way in many tumor types, including breast and lung cancers previously considered poor candidates for such modalities.

Dr. Hauschild Discusses the Dabrafenib BREAK-3 Trial

June 26th 2012

Dr. Axel Hauschild, from University Hospital, Schleswig-Holstein, Germany, Discusses the BREAK-3 Trial That Investigated the BRAF Inhibitor Dabrafenib.

Dr. Topalian on the PD-1 Immunotherapy BMS-936558

June 22nd 2012

Dr. Suzanne Topalian, from the Johns Hopkins University School of Medicine, on the PD-1 Targeted Immunotherapy BMS-936558.

Kathleen Madden on the Importance of Patient Education

June 21st 2012

Kathleen Madden, from NYU Langone Medical Center, on the Importance Educating Patients About Ipilimumab's Side Effects.

Dr. Brahmer on the PD-1 Immunotherapy BMS-936558

June 7th 2012

Dr. Julie Brahmer, from the Sidney Kimmel Comprehensive Cancer Center, on the PD-1 Immunotherapy BMS-93655 Clinical Trial

Two New BRAF-Targeted Therapies Reduce Disease Progression in Advanced Melanoma Patients

June 4th 2012

Trametinib and dabrafenib delayed disease progression and showed a trend toward improved survival in patients with advanced melanoma.